Dear Friends,
Isn't this the point of debate since the start of research ethics
starting from the Tuskeeji study?? I believe this will depend on the
disease under investigation and ofcourse if the standard of care is
not available due to economic reasons then if the company cannot
provide the currently available standard of treatment to set a state
of equipoise then this study should be undertaken in the places where
the alternative therapy is available. Again I stress that every
situation has to be weighed according to risk benefit ratio. I can't
give a final decision whether this is ehtical or not without further
details are given particularly on the type of disease we are talking
about and the risks with and without taking the tested medication.
Thank you for raising this ever lasting point of debate.
--- In EGYPTIAN_RECS@yahoogroups.com, "hanysafwat8" <hanysafwat8@...>
wrote:
>
> Dear friends and colleagues
>
> We all know that guidelines obligate the testing of new drug
against
> standard of care but some time in developing countries like Egypt
where
> standard of care is not available placebo can be considered a
standard
> of care.
>
> Should RECs allow the standard of care in clinical trial to be the
best
> available to study population or best available world-wide?
>
> Your thoughts and why?
>